RXRX vs STZ · rev $14.1M vs P/E 14, rev $9.14B
Recursion Pharmaceuticals Inc (RXRX) versus Constellation Brands Inc Class A (STZ) — a side-by-side from cached financials, not a winner call.
Recursion Pharmaceuticals Inc (RXRX) is a biotechnology company listed on NASDAQ.
Constellation Brands Inc Class A (STZ) is a beverages - brewers company listed on US.
Latest reported RXRX revenue for 2026-06-30 was $14.1M. Net income was -$248.5M. RXRX currently screens at market cap $1.75B.
Latest reported STZ revenue for 2026-02-28 was $9.14B. Net income was $1.69B. Revenue was up 322.3% from 2025-02-28 to 2026-02-28. STZ currently screens at market cap $23.73B and trailing P/E 14.4.
RXRX currently screens at market cap $1.75B. STZ currently screens at market cap $23.73B and trailing P/E 14.4.
Not investment advice. Open the RXRX and STZ stock pages for the full models.
Not investment advice.